Table 1 Demographics and clinical profiles of HBV-infected patients and healthy controls.

From: Correlation of serum hepcidin levels with disease progression in hepatitis B virus-related disease assessed by nanopore film based assay

Parameters

Chronic hepatitis B (N = 16)

HBV-related cirrhosis (N = 14)

HBV-related cirrhosis with HCC (N = 16)

Control (N = 20)

Age (years)

41 ± 12.0

49.6 ± 14.8

54.9 ± 6.8

49 ± 9.0

Gender (M,F)

13, 3

10, 4

14, 2

16, 4

AST (U/L) *

134.7 ± 114

165.3 ± 243.5

90.5 ± 52.3

8–40

ALT (U/L) *

309.4 ± 311.3d

195.6 ± 397.1

75.3 ± 54.4

8–50

ALP (U/L) *

112.3 ± 34.4

121.3 ± 57.0

168.8 ± 98.4

15–112

TBIL (μmol/L) *

23.3 (9.3–613.5)

25.1 (11.1–410.4)

33.6 (12.9–593.9)

6.8–30

Albumin (g/L) *

37.3 ± 4.9c,d

28.3 ± 4.7b

32.3 ± 4.8b

35–55

Hemoglobin (g/L)

147.5 ± 12.5c

125.7 ± 17.5b

137.3 ± 22.2

138 ± 15

HBV-DNA (104 IU/mL) *

244 (4.3–32100)c,d

1.9 (1.05–8720)

26.1 (0.38–346)

0–0.05

Serum iron (μmol/L)

29.4 ± 7.3a

22.1 ± 13.6a

27.6 ± 6.9a

18.6 ± 4.4

TIBC (μmol/L)

60.8 ± 10.7

55.7 ± 11.6

54.3 ± 12.6

75.8 ± 13.7

Ferritin (ng/mL)

672.7 ± 675.2a,c

320.6 ± 237.1a,b,d

501.5 ± 583.3a,c

190 ± 163

CRP *

4.6 ± 5.0

4.4 ± 4.6

4.9 ± 6.3

0–6

  1. Data are summarized as mean ± SD or, in some cases, as median (interquartile range). According to the normality of variable distribution tested by the Kolmogorov-Smirnov test, one-way ANOVA or non-parametric Kruskal-Wallis test was performed for p values. ap < 0.05 vs. control; bp < 0.05 vs. chronic hepatitis B group; cp < 0.05 vs. cirrhosis group; dp < 0.05 vs HCC group. *Reference range given as control values. Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; TBIL, total bilirubin; TIBC, iron and total iron-binding capacity; CRP, C-reactive protein.
Back to article page